SFTPA mutations in interstitial lung disease (ILD) and lung cancer

N. Nathan (Paris, France)

Source: International Congress 2017 – Rare diseases

Session: Rare diseases
Session type: Poster Discussion
Number: 1516

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Nathan (Paris, France). SFTPA mutations in interstitial lung disease (ILD) and lung cancer. 1516

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Telomerase expression in idiopathic pulmonary fibrosis (IPF) and non small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012
Novel lung function tests in patients with interstitial lung disease (ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016
Interstitial fibrosis with a nodule Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session Year: 2007
Lung cancer and interstitial lung disease Source: International Congress 2018 – State of the art session: Thoracic oncology Year: 2018
The association of lung cancer with pulmonary fibrosis Source: ERJ Open Res, 8 (1) 00505-2021; 10.1183/23120541.00505-2021 Year: 2022
The 15q24/25 susceptibility variant for lung cancer and COPD is associated with emphysema Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach Year: 2010
Functional assessment and phenotypic heterogeneity of SFTPA1 and SFTPA2 mutations in interstitial lung diseases and lung cancer Source: Eur Respir J, 56 (6) 2002806; 10.1183/13993003.02806-2020 Year: 2020
Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013
UIP-like or NSIP pattern in interstitial lung disease patients (ILD), following by ‘connective tissue disease ‘(CTD) Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012
Surfactant protein B polymorphisms, pulmonary function and COPD in 10,231 individuals Source: Eur Respir J 2011; 37: 791-799 Year: 2011
WFDC2 (HE4) and SLPI are differentially expressed in normal and diseased human lung and in lung cancer Source: Annual Congress 2006 - Molecular airway biology Year: 2006
Tumour infiltrating lymphocytes and tumour associated macrophages in chronic obstructive pulmonary disease (COPD) patients with non-small cell lung cancer (NSCLC) and in patients with NSCLC Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005
A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Functional assessment of newly identified SFTPA1 and SFTPA2 mutations in patients with idiopathic interstitial pneumonia (IIP) and lung cancer Source: International Congress 2018 – New insights in rare diffuse parenchymal lung diseases (DPLDs) in adults and children Year: 2018
The TERT-CLPTM1L locus for lung cancer predisposes to bronchial obstruction and emphysema Source: Eur Respir J 2011; 38: 924-931 Year: 2011
Siphonage lung disease Source: Virtual Congress 2020 – Respiratory critical care Year: 2020
Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015